Mary Sullivan

Dexpramipexole effectively lowers blood and tissue eosinophils in subjects with chronic rhinosinusitis with nasal polyps

R. Panettieri, N. Adappa, S. Dworetzky, 2017 .

Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study

A. Signore, C. Dunbar, S. Dworetzky, 2016 .

Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size

R. Panettieri, N. Adappa, S. Dworetzky, 2018, The Laryngoscope.

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.

M. Fay, C. Dunbar, S. Dworetzky, 2018, Blood.

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

V. Gribkoff, D. Schoenfeld, M. Cudkowicz, 2011, Nature Medicine.